24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Depression: Depression & Related Conditions
Resources
Basic Information
Introduction and Types of Depressive DisordersRelated Disorders / ConditionsHistorical and Current UnderstandingsBiology, Psychology and SociologyTreatment - Medication and PsychotherapyAlternative Medicine and Self-Help ResourcesSpecial IssuesReferences
More InformationTestsLatest News
Experimental Drug Works Quickly on Major DepressionExercise Your Blues AwayDepression, Alzheimer's Might Be Part of Same Process in Some Aging Brains: StudyToo Much Social Media a Depression Risk for TeensEasing Depression Can Bring Longer Life to People With DiabetesIs Your Child Depressed or Suicidal? Here Are the Warning SignsDepression Plus HIV Can Turn DeadlyBrain Stimulation May Soothe Severe DepressionFussy Baby May Raise Mom's Risk of DepressionAbuse in Childhood Tied to Brain Changes and Later DepressionFDA Approves First Drug for Postpartum DepressionNutritional Supplements Don't Ward Off Depression: StudyFDA Approves Ketamine-Like Drug for Severe DepressionFDA Poised to Approve Ketamine-Like Drug to Ease DepressionAcne Drug Accutane May Not Depress Mood After AllHealth Tip: Beat the Winter BluesAHA News: Post-Stroke Depression Common Among Black, Hispanic SurvivorsHealth Tip: Recognizing Signs of Depression in TeensCould Germs in Your Gut Send You Into Depression?Simple Treatments to Banish Winter BluesMillennials' Odds for Depression Rise With Social Media UseListen Up! Hearing Loss Tied to Late-Life DepressionHealth Tip: Risk Factors for Depression After PregnancyHead to the Movies, Museums to Keep Depression at BayThe Link Between Social Media and DepressionMany Say Ketamine Eased Their Depression, But Is It Safe?Docs Should Screen for Depression During, After PregnancyBrexit Had Brits Turning to Antidepressants: StudyDepression Is a Risk for Teens, Adults With EpilepsyStimulating One Brain Area May Ease Tough-to-Treat DepressionAnti-Seizure Drug May Be New Weapon Against DepressionMichael Phelps Champions the Fight Against DepressionFacebook Posts May Hint at DepressionDo Dimmer Days in Pregnancy Raise Postpartum Depression Risk?Preventive Intervention for Premature Infants Effective
Questions and AnswersLinks
Related Topics

Anxiety Disorders
Bipolar Disorder
Suicide
Addictions: Alcohol and Substance Abuse
Pain Management

Experimental Drug Works Quickly on Major Depression

HealthDay News
by By Serena GordonHealthDay Reporter
Updated: Sep 4th 2019

new article illustration

WEDNESDAY, Sept. 4, 2019 (HealthDay News) -- Antidepressants typically take four to eight weeks to ease the debilitating symptoms of depression, but an early clinical trial found a new type of drug brought relief in just two weeks.

"SAGE-217, once fully developed, has potential to offer relatively quick and clinically meaningful alleviation of depressive symptoms in patients with moderate to severe major depressive disorder," said study author Dr. Handan Gunduz-Bruce, from Sage Therapeutics in Cambridge, Mass.

The study was published in the Sept. 5 issue of the New England Journal of Medicine. Funding for the study was provided by the drug maker, Sage Therapeutics.

In an editorial in the same issue of the journal, Dr. Emil Coccaro, a professor of psychiatry at the Pritzker School of Medicine, University of Chicago, noted that up to 16% of people experience major depression in their lifetimes. People with major depression have a higher risk of suicide, he said.

Only about 60% with major depression respond to currently available antidepressants, according to Coccaro.

"Anything that can make depression better quickly is a good thing. This is a very novel drug and it may work faster than standard antidepressants on the market, but it's an early study," Coccaro said, adding that if additional trials go well, it would still likely be at least several years before this drug could be on the market.

The new drug affects the way the brain uses a neurotransmitter called gamma-aminobutyric acid (GABA). Other depression medications affect different types of neurotransmitters in the brain, such as serotonin. Neurotransmitters are chemical messengers that send information between brain cells.

Dr. Timothy Sullivan, chair of psychiatry and behavioral sciences at Northwell Health's Staten Island University Hospital in New York City, explained that the GABA system monitors and regulates activity in the brain, slowing things down.

The study was a phase 2 clinical trial. It included 89 people with major depression. Half of the group was given SAGE-217 daily for two weeks. The other half was given a placebo pill each day.

At the start of the study, the volunteers scored an average of around 25 on a depression test. After two weeks, scores for those taking the drug dropped more than 17 points, while those on placebo went down only 10 points, the investigators found.

"With just two weeks of treatment, we saw a clinically meaningful response in depressed patients," Gunduz-Bruce said, noting that most antidepressants take four to eight weeks to work.

The most common side effects reported were headache, dizziness, nausea and feeling sleepy.

Gunduz-Bruce said the researchers are now conducting longer-term trials.

The drug can be used alone or in conjunction with another antidepressant, she said.

Coccaro noted that the current trial didn't include anyone with treatment-resistant depression, and that this group includes a "fair amount" of people with major depression.

Gunduz-Bruce said the researchers are planning to study how well the drug works with treatment-resistant depression.

Sullivan said the current study was "exciting and intriguing," but also said that it's still early. He said it was good to see a medication being developed that addresses a new pathway in the brain.

"If these findings hold up, this drug has the potential for being a much easier drug to tolerate," Sullivan said. He added that's important because many people have difficulty with the side effects of some current treatments, such as feeling as if their emotions are blunted, weight gain and loss of interest in sex.

The bottom line, according to Coccaro, is that this study is "very encouraging, but the sample size is small. When more people are studied, how well will the effect hold up?"

More information

Learn more about depression and available treatments from the U.S. Food and Drug Administration.